<DOC>
	<DOCNO>NCT02850484</DOCNO>
	<brief_summary>The objective pivotal study evaluate relative bioavailability SYN010 HFA Inhaler Symbicort 160/4.5μg healthy volunteer charcoal block .</brief_summary>
	<brief_title>A Bioequivalence Pivotal Study SYN010 HFA Inhaler Symbicort® 160/4.5 Healthy Volunteers With Charcoal Block</brief_title>
	<detailed_description>A pivotal , single-dose , randomize , open-label , partial replicate , three-period , three-sequence , two-treatment , three-way crossover , comparative bioavailability study . Ninety-nine , male female volunteer , 20-45 year age , body mass index ( BMI ) within 18.5-30.0 kg/m2 , inclusive , enrol . ( The body weight 50 kg , inclusive , respectively ) A single dose 8 puff ( equivalent budesonide 1280 μg/formoterol fumarate dihydrate 36 μg ) study period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>1 . Healthy male female volunteer , age 2045 , inclusive . 2 . BMI within 18.530.0 kg/m² , inclusive . ( The body weight 50 kg , inclusive , respectively ) 3 . Healthy Non Clinical Significant , accord medical history , Electrocardiography ( ECG ) , Chest Xray physical examination determine Principal Investigator/SubInvestigator . 4 . Systolic blood pressure 90139 mmHg , inclusive , diastolic blood pressure 5090 mmHg , inclusive , pulse rate 50100 bpm , inclusive temperature 35.037.4°C . 5 . Clinical laboratory value within reference range NonClinical Significance ( NCS ) judge Principal Investigator/SubInvestigator . 6 . Ability comprehend inform nature study . Capable give write informed consent prior receive study medication . Must able communicate effectively clinic staff . 7 . Ability fast least 14 hour consume standard meal . 8 . Availability volunteer entire study duration willing adhere protocol requirement . 9 . Agree tattoo body pierce end study . 10 . Female subject must fulfill least one following : Be surgically sterile minimum 6 month ; Postmenopausal minimum 1 year ; Agree avoid pregnancy use medically acceptable method contraception screen day 30 day study end ( last study procedure ) . 1 . Known history presence clinically significant hepatic ( e.g . active liver disease , hepatic impairment ) , renal/genitourinary ( e.g . renal impairment ) , gastrointestinal , cardiovascular , cerebrovascular , pulmonary , endocrine ( e.g . hypothyroidism ) , immunological , musculoskeletal ( e.g . myopathy , rhabdomyolysis ) , neurological , psychiatric , dermatological hematological disease condition unless determine clinically significant Principal Investigator/SubInvestigator . 2 . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , condition know interfere absorption , distribution , metabolism excretion drug experience within 7 day prior first drug administration , determine Principal Investigator/Sub Investigator . 3 . Presence clinically significant illness within 30 day prior first dosing , determine Principal Investigator/SubInvestigator . 4 . Presence significant physical organ abnormality determine Principal Investigator/SubInvestigator . 5 . A positive test result follow : Human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen , Hepatitis C , drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine , tetrahydrocannabinol ) , breath alcohol test . Positive pregnancy test female subject . 6 . Known history presence : Alcohol abuse dependence within one year prior first drug administration ; Drug abuse dependence ; Hypersensitivity idiosyncratic reaction budesonide , formoterol fumarate dihydrate , excipients , and/or related substance ; Food allergy and/or presence dietary restriction ; Severe allergic reaction ( e.g . anaphylactic reaction , angioedema ) . 7 . Intolerance and/or difficulty blood sample venipuncture . 8 . Abnormal diet pattern ( reason ) four week precede study , include fasting , high protein diet etc . 9 . Individuals donate , day prior first drug administration : Less 250 mL blood previous 60 day 300 mL previous 90 day 10 . Donation plasma plasmapheresis within 7 day prior first drug administration . 11 . Individuals participate another clinical trial receive investigational drug within 30 day prior first drug administration . 12 . Consumption food beverage contain caffeine/methylxanthines , poppy seed and/or alcohol within 48 hour dose contain grapefruit and/or pomelo within 10 day prior first drug administration . 13 . Use prescription medication within 30 day prior first drug administration . 14 . Use overthecounter medication ( include oral multivitamin , herbal and/or dietary supplement ) within 30 day prior first drug administration ( except spermicidal/barrier contraceptive product ) . 15 . Females take oral transdermal hormonal contraceptive within 30 day prior first drug administration . 16 . Females use implant , inject , intravaginal , intrauterine hormonal contraceptive within 6 month prior first drug administration . 17 . Individuals undergone major surgery within 6 month prior start study , unless deem otherwise Principal Investigator/SubInvestigator . 18 . Known history smoke use tobacco product , nicotine product ( patch , gum etc . ) within 6 month prior first drug administration . 19 . Pregnant/lactating woman . 20 . Subjects give train ensure subject able correctly use investigational product screen . The subject unable operate investigational product proficiently include study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>